What is Ginkgo Bioworks's market cap?

Ginkgo Bioworks (DNA) has a market capitalization of $486.7M and trades on NYSE.

What is Ginkgo Bioworks's revenue and profitability?

Ginkgo Bioworks generated $141.3M in trailing twelve-month revenue with a net loss of $304.4M, representing a net margin of -215.4%, with free cash flow of -$168.2M. These figures are based on the Q1 2026 filing.

Who are Ginkgo Bioworks's competitors?

Ginkgo Bioworks's key competitors include Charles River Laboratories, Codexis, AbCellera, and others. These companies compete in similar markets and product categories.

Who does Ginkgo Bioworks partner with?

Ginkgo Bioworks's notable partners include Google Cloud, Bayer Crop Science, Virica Biotech, and others.

What subsidiaries does Ginkgo Bioworks have?

Ginkgo Bioworks's subsidiaries include Zymergen.

Where is Ginkgo Bioworks headquartered?

Ginkgo Bioworks is headquartered in United States of America and employs approximately 1,218 people. It has been publicly traded since 2021.

Ginkgo Bioworks

DNA

Ginkgo Bioworks operates a horizontal platform for cell engineering and biosecurity, designed to make biology easier to engineer through automation, software, and data.

Market cap

$486.67M-35.4%

Revenue$141.3M-37.8%

Net income-$304.4M+35.5%

Free cash flow-$168.2M+51.3%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$19.5MMiss by $23.5M EPS-$1.28Miss by $0.07

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$24.1M

EPS estimate-$0.90

Financials

Q1 2026

Income statement

See full

Revenue$19.5M-49.1%

Gross profit$16.4M-52.0%

Operating income-$71.4M+11.9%

Net income-$82.6M+9.2%

Balance sheet

See full

Cash & equivalents$188.7M-46.9%

Total debt$410.7M-5.5%

Total equity$443.2M-31.6%

Total assets$1.0B-20.1%

Cash flow

See full

Operating cash flow-$46.7M+9.4%

CapEx$1.9M-74.6%

Free cash flow-$48.6M+17.8%

Valuation & ratios

Valuation

See full

Market cap$486.67M-35.4%

Enterprise value$708.7M-28.7%

P/S3.4×-0.3×

Profitability

See full

Operating margin-210.7%+7.6pp

Net margin-215.4%+8.3pp

FCF margin-119%-21.2pp

Returns & leverage

See full

Return on equity-55.8%-1.8pp

Debt / equity0.9×+0.3×

Current ratio5.2×+0.3×

Segments

By segment

See full

Reportable Segment$19.5M—

Competitors

By market cap

Thermo Fisher Scientific$207.93B+13.6%

TEC

Bio-Techne$11.2B+21.6%

Charles River Laboratories$10.8B+22.9%

AbCellera Biologics Inc.$1.6B+9.2%

Ginkgo Bioworks$486.7M-40.4%

Codexis$140.9M-44.1%

Boundless Bio, Inc.$55.7M+101%

Impact BioMedical$46.6M-34.6%

By revenue growth

AbCellera Biologics Inc.+243%

Thermo Fisher Scientific+5.6%

TEC

Bio-Techne+0.2%

Charles River Laboratories+0.1%

Ginkgo Bioworks-37.8%

By net margin

Thermo Fisher Scientific15.19%0.0pp

TEC

Bio-Techne10.89%-0.7pp

Charles River Laboratories-4.59%-11.1pp

AbCellera Biologics Inc.-181.75%+544pp

Ginkgo Bioworks-215.41%-7.7pp

Profile

Ginkgo Bioworks operates a horizontal platform for cell engineering and biosecurity, designed to make biology easier to engineer through automation, software, and data. The company provides biological R&D services and tools to customers across diverse industries, enabling them to discover, optimize, and manufacture bio-based products without maintaining extensive in-house laboratory infrastructure.

Competitive position

A leading horizontal platform provider that competes by offering scale and automation efficiencies that exceed traditional 'by-hand' laboratory R&D.

GeographiesGlobal, United States

Customer segmentsEnterprise, Government, Academic Institutions

Business modelR&D services, Platform-as-a-Service, Licensing, Royalty-based

SuppliersLife science tool manufacturers, DNA synthesis providers, Cloud computing providers, Laboratory consumable distributors

CustomersDrug developers, Food and nutrition companies, Crop protection manufacturers, Public health agencies

CountryUnited States of America

Listed2021

Employees1.2K

CEOJason Kelly

SectorHealthcare

IndustryBiotechnology

Websiteginkgobioworks.com

FilingsSEC EDGAR

Ask your AI about Ginkgo Bioworks.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ginkgo Bioworks's market cap?: Ginkgo Bioworks (DNA) has a market capitalization of $486.7M and trades on NYSE.
What is Ginkgo Bioworks's revenue and profitability?: Ginkgo Bioworks generated $141.3M in trailing twelve-month revenue with a net loss of $304.4M, representing a net margin of -215.4%, with free cash flow of -$168.2M. These figures are based on the Q1 2026 filing.
Who are Ginkgo Bioworks's competitors?: Ginkgo Bioworks's key competitors include Charles River Laboratories, Codexis, AbCellera, and others. These companies compete in similar markets and product categories.
Who does Ginkgo Bioworks partner with?: Ginkgo Bioworks's notable partners include Google Cloud, Bayer Crop Science, Virica Biotech, and others.
What subsidiaries does Ginkgo Bioworks have?: Ginkgo Bioworks's subsidiaries include Zymergen.
Where is Ginkgo Bioworks headquartered?: Ginkgo Bioworks is headquartered in United States of America and employs approximately 1,218 people. It has been publicly traded since 2021.